These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19802978)

  • 1. Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents.
    Mouton RP; Bongaerts GP; van Gestel MH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():147-52. PubMed ID: 19802978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L; Dornbusch K; Hallander HO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():163-7. PubMed ID: 19802980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
    Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behaviour of ceftazidime towards beta-lactamases.
    Labia R; Beguin-Billecoq R; Guionie M
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():141-6. PubMed ID: 19810176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.
    Verbist L
    Antimicrob Agents Chemother; 1981 Mar; 19(3):407-13. PubMed ID: 6972728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of first, second and third generation cephalosporins.
    Forsgren A
    Acta Pathol Microbiol Scand B; 1981 Aug; 89(4):221-5. PubMed ID: 6274143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M
    Antimicrob Agents Chemother; 1979 Dec; 16(6):757-60. PubMed ID: 316989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in-vitro activity of ceftazidime (GR-20263) and other beta-lactamase stable cephalosporins against anaerobic bacteria.
    Chow AW; Bartlett KH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():91-5. PubMed ID: 19802974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefoxitin sensitivity as a marker for inducible beta-lactamases.
    Moritz VA; Carson PB
    J Med Microbiol; 1986 May; 21(3):203-7. PubMed ID: 3486293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro activities of eight new beta-lactam compounds against cephalothin-resistant Enterobacteriaceae from hospital patients.
    Costopoulos C; Legakis NJ; Papafragas E; Marinis E
    Chemotherapy; 1984; 30(3):158-64. PubMed ID: 6610538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.
    Sanders CC; Sanders WE
    Antimicrob Agents Chemother; 1979 Jun; 15(6):792-7. PubMed ID: 314270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro evaluation of moxalactam on enterobacteria producing beta-lactamases].
    Kazmierczak A; Pechinot A; Duez JM; Kohli E; Tremeaux JC
    Sem Hop; 1983 Jun; 59(26):1953-7. PubMed ID: 6310785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity and beta-lactamase stability of moxalactam and other selected cephalosporin antibiotics.
    Vuye A
    Arzneimittelforschung; 1981; 31(8):1290-5. PubMed ID: 6457607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of ceftazidime on enterobacteria and Pseudomonas producers of beta-lactamases].
    Chabbert YA; Derlot E; Courvalin P
    Pathol Biol (Paris); 1985 Sep; 33(7):758-63. PubMed ID: 3936006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in-vitro activity of ceftazidime (GR 20263) and other beta-lactamase stable cephalosporins against pseudomonas. Effect of inoculum size and divalent cation supplementation.
    Chow AW; Bartlett KH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():345-8. PubMed ID: 19803012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.